CHST4

Summary

CHST4 (carbohydrate sulfotransferase 4, HGNC:1972) is a protein-coding gene on chromosome 16q22.2, encoding Carbohydrate sulfotransferase 4 (Q8NCG5). Sulfotransferase involved in SELL/L-selectin ligand biosynthesis pathway.

This gene encodes an N-acetylglucosamine 6-O sulfotransferase. The encoded enzyme transfers sulfate from 3’phosphoadenosine 5’phospho-sulfate to the 6-hydroxyl group of N-acetylglucosamine on glycoproteins. This protein is localized to the Golgi and is involved in the modification of glycan structures on ligands of the lymphocyte homing receptor L-selectin. Alternate splicing in the 5’ UTR results in multiple transcript variants that encode the same protein.

Source: NCBI Gene 10164 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 79 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_001166395

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1972
Approved symbol	CHST4
Name	carbohydrate sulfotransferase 4
Location	16q22.2
Locus type	gene with protein product
Status	Approved
Aliases	HEC-GLCNAC-6-ST, LSST
Ensembl gene	ENSG00000140835
Ensembl biotype	protein_coding
Entrez	10164

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 retained_intron

ENST00000338482, ENST00000539698, ENST00000572693, ENST00000866592, ENST00000927526, ENST00000927527

RefSeq mRNA: 2 — MANE Select: NM_001166395 NM_001166395, NM_005769

CCDS: CCDS10902

Canonical transcript exons

ENST00000539698 — 2 exons

Exon	Start	End
ENSE00002270267	71526426	71526495
ENSE00002635842	71536660	71538748

Expression profiles

Bgee: expression breadth broad, 94 present calls, max score 95.78.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2913 / max 55.5294, expressed in 76 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
154920	0.1550	57
154917	0.0611	29
154918	0.0495	26
154919	0.0258	8

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gall bladder	UBERON:0002110	95.78	gold quality
pancreatic ductal cell	CL:0002079	90.82	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.75	gold quality
epithelial cell of pancreas	CL:0000083	84.62	gold quality
islet of Langerhans	UBERON:0000006	75.90	gold quality
ileal mucosa	UBERON:0000331	74.49	gold quality
pancreas	UBERON:0001264	73.21	gold quality
body of pancreas	UBERON:0001150	72.19	gold quality
epithelium of bronchus	UBERON:0002031	71.22	gold quality
bronchus	UBERON:0002185	70.12	gold quality
secondary oocyte	CL:0000655	70.07	gold quality
sperm	CL:0000019	69.92	gold quality
cervix squamous epithelium	UBERON:0006922	69.65	gold quality
nasal cavity epithelium	UBERON:0005384	69.48	gold quality
male germ cell	CL:0000015	69.45	gold quality
bronchial epithelial cell	CL:0002328	69.15	gold quality
tibialis anterior	UBERON:0001385	68.74	silver quality
oviduct epithelium	UBERON:0004804	68.47	silver quality
germinal epithelium of ovary	UBERON:0001304	68.40	silver quality
right lobe of liver	UBERON:0001114	67.35	gold quality
liver	UBERON:0002107	65.72	gold quality
right uterine tube	UBERON:0001302	65.40	gold quality
right adrenal gland cortex	UBERON:0035827	64.89	gold quality
palpebral conjunctiva	UBERON:0001812	64.69	silver quality
right adrenal gland	UBERON:0001233	64.29	gold quality
fallopian tube	UBERON:0003889	63.73	gold quality
left adrenal gland	UBERON:0001234	63.66	gold quality
left adrenal gland cortex	UBERON:0035825	63.15	gold quality
epithelium of nasopharynx	UBERON:0001951	62.68	silver quality
adrenal cortex	UBERON:0001235	61.89	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-130473	yes	1215.44
E-MTAB-10553	yes	20.49
E-HCAD-9	yes	8.61
E-ANND-3	no	3.10

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA3, SP1, TBX21

miRNA regulators (miRDB)

30 targeting CHST4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-4756-3P	99.62	66.30	1319
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-2113	99.58	71.22	1521
HSA-MIR-892A	99.54	68.16	1141
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-6740-3P	99.48	68.49	1392
HSA-MIR-4762-3P	99.43	69.72	2363
HSA-MIR-1264	99.25	66.81	1317
HSA-MIR-6809-5P	99.13	68.45	1223
HSA-MIR-6884-5P	99.10	64.50	1987
HSA-MIR-10A-5P	98.89	69.85	712
HSA-MIR-10B-5P	98.89	69.86	711
HSA-MIR-2355-5P	98.83	65.51	1589
HSA-MIR-2467-3P	98.65	67.18	1969
HSA-MIR-3192-3P	98.62	65.80	970
HSA-MIR-1237-3P	98.55	67.65	1423
HSA-MIR-7114-5P	98.51	67.87	1349
HSA-MIR-3138	98.41	67.53	744
HSA-MIR-6509-3P	98.32	67.33	1343
HSA-MIR-653-3P	98.31	67.71	1542
HSA-MIR-4305	97.94	68.63	533
HSA-MIR-3670	97.88	64.39	763
HSA-MIR-146B-3P	97.83	65.29	782
HSA-MIR-4475	97.36	66.95	761
HSA-MIR-4661-3P	96.81	66.02	342
HSA-MIR-6806-5P	96.37	68.74	587

Literature-anchored findings (GeneRIF, showing 6)

• Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma (PMID:12107080)
• involved in enzymatic synthesis in vitro of the disulfated disaccharide unit of corneal keratan sulfate (PMID:12218059)
• GlcNAc6ST2 could therefore be a good serological marker for detecting early-stage uterine cervical and corpus cancers. (PMID:19156517)
• A method for O-GlcNAc detection using in vitro sulfation with two N-acetylglucosamine (GlcNAc)-specific sulfotransferases, carbohydrate sulfotransferase 2 and carbohydrate sulfotransferase 4. (PMID:24799377)
• Data suggest that GlcNAc6ST-2 (CHST4) is critical for biosynthesis of MECA-79 sulfated glycans in apical membranes of small-sized intrahepatic bile ducts and of cholangiolocellular carcinoma (CoCC) cells; MUC1 protein decorated with GlcNAc6ST-2-dependent MECA-79 sulfated glycans may serve as a useful CoCC marker. (PMID:27748735)
• mRNA transcript analyses on the genes involved in synthesizing GlcNAc-6-O-sulfated glycans in human colon cancer tissues indicated that GlcNAc6ST-2 (CHST4) is preferentially expressed in cancer cells … GlcNAc6ST-3 (CHST5) was only expressed in nonmalignant epithelial cells, whereas GlcNAc6ST-1 (CHST2) was expressed equally in both cancerous and nonmalignant epithelial cells. (PMID:30093410)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Chst4	ENSMUSG00000035930
rattus_norvegicus	Chst4	ENSRNOG00000016953
drosophila_melanogaster	CG9550	FBGN0031826
drosophila_melanogaster	CG31637	FBGN0051637

Paralogs (6): CHST3 (ENSG00000122863), CHST5 (ENSG00000135702), CHST7 (ENSG00000147119), CHST2 (ENSG00000175040), CHST1 (ENSG00000175264), CHST6 (ENSG00000183196)

Protein

Protein identifiers

Carbohydrate sulfotransferase 4 — Q8NCG5 (reviewed: Q8NCG5)

Alternative names: Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 3, High endothelial cells N-acetylglucosamine 6-O-sulfotransferase, L-selectin ligand sulfotransferase, N-acetylglucosamine 6-O-sulfotransferase 2

All UniProt accessions (1): Q8NCG5

UniProt curated annotations — full annotation on UniProt →

Function. Sulfotransferase involved in SELL/L-selectin ligand biosynthesis pathway. Catalyzes the transfer of the sulfate group from 3’-phospho-5’-adenylyl sulfate (PAPS) onto the hydroxyl group at C-6 position of the non-reducing N-acetylglucosamine (GlcNAc) residue within O-linked mucin-type glycans. Contributes to generate sialyl 6-sulfo Lewis X determinant (also known as MECA-79 epitope) for SELL recognition, a prerequisite for continuous lymphocyte homing into peripheral lymph nodes and antigen immune surveillance. Transfers the sulfate group primarily on core 2 GlcNAcbeta1-6(Galbeta1-3)GalNAcalphaSer/Thr and extended core 1 GlcNAcbeta1-3Galbeta1-3GalNAcalphaSer/Thr based O-linked glycans on CD34 and GLYCAM1 peripheral node addressins (PNAds) expressed on the lumenal side of high endothelial venules (HEVs). The recognition of PNAds by SELL initiates a multistep process comprising tethering and rolling of blood lymphocytes on HEVs against the blood flow, followed by chemokine signaling, integrin-mediated lymphocyte adhesion onto endothelial cells and lymphocyte transendothelial migration. Modulates rolling velocity and differential T and B lymphocyte recruitment into peripheral lymph nodes, with a major role in B lymphocyte homing. Might be redundant in sulfation of MADCAM1 and lymphocyte trafficking to mesenteric lymph nodes. Can also sulfonate core 3 GlcNAcbeta1-3GalNAc-R based glycans as well as GlcNAcbeta1-3Galbeta1-Glc, GlcNAcbeta1-6ManOMe and GlcNAcbeta1-2Man oligosaccharides, which might be ectopically expressed during tumorigenesis.

Subunit / interactions. Monomer.

Subcellular location. Golgi apparatus membrane.

Tissue specificity. Specifically expressed in HEV. Weakly expressed in spleen. Not expressed in other tissues. Expressed in colonic mucinous adenocarcinoma.

Induction. Upon cytokine activation, it is expressed at low level.

Pathway. Protein modification; carbohydrate sulfation.

Miscellaneous. May serve as an anti-inflammatory target.

Similarity. Belongs to the sulfotransferase 1 family. Gal/GlcNAc/GalNAc subfamily.

RefSeq proteins (2): NP_001159867, NP_005760 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000863	Sulfotransferase_dom	Domain
IPR016469	Carbohydrate_sulfotransferase	Family
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR051135	Gal/GlcNAc/GalNAc_ST	Family

Pfam: PF00685

Catalyzed reactions (Rhea), 4 shown:

• 3-O-{N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl}-L-threonyl-[protein] + 3’-phosphoadenylyl sulfate = 3-O-{6-O-sulfo-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl}-L-threonyl-[protein] + adenosine 3’,5’-bisphosphate + H(+) (RHEA:67856)
• 3-O-{N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl}-L-seryl-[protein] + 3’-phosphoadenylyl sulfate = 3-O-{6-O-sulfo-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl}-L-seryl-[protein] + adenosine 3’,5’-bisphosphate + H(+) (RHEA:67860)
• a 3-O-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-threonyl-[protein] + 3’-phosphoadenylyl sulfate = 3-O-{beta-D-galactosyl-(1->3)-[6-O-sulfo-N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-threonyl-[protein] + adenosine 3’,5’-bisphosphate + H(+) (RHEA:67864)
• 3-O-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl-[protein] + 3’-phosphoadenylyl sulfate = 3-O-{beta-D-galactosyl-(1->3)-[6-O-sulfo-N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl-[protein] + adenosine 3’,5’-bisphosphate + H(+) (RHEA:67868)

UniProt features (11 total): glycosylation site 3, topological domain 2, binding site 2, chain 1, sequence conflict 1, transmembrane region 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NCG5-F1	90.66	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 51–57; 205–213

Glycosylation sites (3): 30, 308, 329

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-913709	O-linked glycosylation of mucins

MSigDB gene sets: 113 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, AP1_01, chr16q22, GOBP_INFLAMMATORY_RESPONSE, GOBP_SULFATION, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_CELL_CELL_SIGNALING, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, GOBP_CELL_CELL_ADHESION, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_CELLULAR_EXTRAVASATION, GOBP_LEUKOCYTE_MIGRATION, AP1_Q4_01, GOCC_TRANS_GOLGI_NETWORK

GO Biological Process (10): carbohydrate metabolic process (GO:0005975), N-acetylglucosamine metabolic process (GO:0006044), protein sulfation (GO:0006477), sulfur compound metabolic process (GO:0006790), inflammatory response (GO:0006954), immune response (GO:0006955), cell adhesion (GO:0007155), cell-cell signaling (GO:0007267), protein O-linked glycosylation via N-acetylgalactosamine (GO:0016266), positive regulation of leukocyte tethering or rolling (GO:1903238)

GO Molecular Function (3): N-acetylglucosamine 6-O-sulfotransferase activity (GO:0001517), sulfotransferase activity (GO:0008146), transferase activity (GO:0016740)

GO Cellular Component (4): Golgi membrane (GO:0000139), trans-Golgi network (GO:0005802), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
O-linked glycosylation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
primary metabolic process	1
amino sugar metabolic process	1
protein modification process	1
sulfation	1
metabolic process	1
defense response	1
immune system process	1
response to stimulus	1
cellular process	1
cell communication	1
signaling	1
protein O-linked glycosylation	1
leukocyte tethering or rolling	1
regulation of leukocyte tethering or rolling	1
positive regulation of leukocyte adhesion to vascular endothelial cell	1
sulfotransferase activity	1
transferase activity, transferring sulphur-containing groups	1
catalytic activity	1
Golgi apparatus	1
bounding membrane of organelle	1
Golgi apparatus subcompartment	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

466 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CHST4	NTAN1	Q96AB6	962
CHST4	SELL	P14151	721
CHST4	FUT7	Q11130	678
CHST4	ST3GAL6	Q9Y274	605
CHST4	GCNT1	Q02742	586
CHST4	CD300LG	Q6UXG3	578
CHST4	B3GNT3	Q9Y2A9	578
CHST4	MADCAM1	Q13477	518
CHST4	HECA	Q9UBI9	505
CHST4	B3GNT6	Q6ZMB0	479
CHST4	MIMS2	Q96KR6	458
CHST4	EMCN	Q9ULC0	449
CHST4	LUM	P51884	445
CHST4	B3GNT2	Q9NY97	437
CHST4	CHST13	Q8NET6	432

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CHST6	CANX	psi-mi:“MI:0914”(association)	0.530
DCPS	CHST4	psi-mi:“MI:0915”(physical association)	0.370
CHST6	HSPA5	psi-mi:“MI:0914”(association)	0.350

BioGRID (8): CHST4 (Affinity Capture-MS), CHST4 (Affinity Capture-MS), CHST4 (Affinity Capture-MS), CHST4 (Affinity Capture-MS), CHST4 (Cross-Linking-MS (XL-MS)), FAM91A1 (Cross-Linking-MS (XL-MS)), KIDINS220 (Cross-Linking-MS (XL-MS)), DCPS (Two-hybrid)

ESM2 similar proteins: A2VDP6, A4D0V7, B1WB06, F1N2K1, O43548, P06802, P15396, P22413, P50127, P79949, P97259, Q05004, Q08834, Q08BN9, Q09328, Q14C87, Q14DG7, Q2TU62, Q3L7M0, Q3U095, Q52KP5, Q5R748, Q5RCA5, Q5XI89, Q5ZLK4, Q6AX23, Q6DNG6, Q6UWF7, Q6ZXA0, Q76HP2, Q76HP3, Q86UX2, Q8BG22, Q8C7K6, Q8K1B9, Q8N323, Q8NCG5, Q8NHY0, Q8R4G6, Q8VI38

Diamond homologs: O43916, O88199, O93403, Q0VBN2, Q5RJQ0, Q6DBY9, Q6XQG8, Q7LGC8, Q80WV3, Q8IZU8, Q8NCG5, Q92179, Q9EP78, Q9EQC0, Q9GZS9, Q9GZX3, Q9NS84, Q9QUP4, Q9QZL2, Q9R1I1, Q9Y4C5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

79 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	67
Likely benign	10
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1706519	GRCh37/hg19 16q22.1-23.1(chr16:68971067-74823560)x1	Pathogenic

SpliceAI

489 predictions. Top by Δscore:

Variant	Effect	Δscore
16:71525376:G:GT	donor_gain	1.0000
16:71525376:G:T	donor_gain	0.9900
16:71525386:C:G	donor_gain	0.9900
16:71536655:TAAA:T	acceptor_loss	0.9900
16:71536657:AAGG:A	acceptor_loss	0.9900
16:71536658:A:C	acceptor_loss	0.9900
16:71536659:G:A	acceptor_loss	0.9900
16:71525382:GCAGC:G	donor_gain	0.9700
16:71536644:T:TA	acceptor_loss	0.9700
16:71525410:TGGGA:T	donor_gain	0.9600
16:71536657:A:G	acceptor_gain	0.9600
16:71536658:A:AG	acceptor_gain	0.9600
16:71536659:G:GG	acceptor_gain	0.9600
16:71525927:C:T	donor_gain	0.9500
16:71536656:A:AG	acceptor_gain	0.9300
16:71536375:T:G	donor_gain	0.8900
16:71536754:T:G	acceptor_gain	0.8800
16:71525377:A:T	donor_gain	0.8700
16:71536374:GT:G	donor_gain	0.8600
16:71536375:TT:T	donor_gain	0.8600
16:71525883:GC:G	donor_gain	0.8500
16:71536373:GGT:G	donor_gain	0.8500
16:71525402:G:A	donor_gain	0.8400
16:71525420:T:TG	donor_gain	0.8400
16:71525414:A:T	donor_gain	0.8300
16:71536344:G:GT	donor_gain	0.8300
16:71536656:AAAG:A	acceptor_gain	0.8300
16:71525401:G:A	donor_gain	0.7900
16:71536659:GGT:G	acceptor_gain	0.7900
16:71525397:G:A	donor_gain	0.7800

AlphaMissense

2550 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:71537208:G:C	K177N	0.994
16:71537208:G:T	K177N	0.994
16:71537679:G:C	W334C	0.993
16:71537679:G:T	W334C	0.993
16:71536823:C:T	S49F	0.990
16:71536895:A:T	E73V	0.990
16:71536987:T:A	C104S	0.990
16:71536988:G:C	C104S	0.990
16:71537677:T:A	W334R	0.990
16:71537677:T:C	W334R	0.990
16:71536889:T:C	L71P	0.989
16:71537179:T:A	C168S	0.989
16:71537180:G:C	C168S	0.989
16:71536832:G:C	R52P	0.988
16:71537291:G:C	R205P	0.988
16:71537294:A:G	D206G	0.988
16:71536988:G:A	C104Y	0.987
16:71536988:G:T	C104F	0.987
16:71537062:A:C	S129R	0.987
16:71537064:C:A	S129R	0.987
16:71537064:C:G	S129R	0.987
16:71537180:G:A	C168Y	0.987
16:71537181:C:G	C168W	0.987
16:71537294:A:C	D206A	0.987
16:71537294:A:T	D206V	0.987
16:71537318:G:C	R214P	0.987
16:71537215:C:A	R180S	0.986
16:71536823:C:A	S49Y	0.985
16:71536831:C:A	R52S	0.985
16:71536840:T:C	S55P	0.985

dbSNP variants (sampled 300 via entrez): RS1000347043 (16:71536501 T>C), RS1000359803 (16:71530270 C>T), RS1000451048 (16:71535896 A>G), RS1000858628 (16:71525192 T>C), RS1000903728 (16:71531652 G>A,T), RS1000964757 (16:71524578 T>C), RS1001093906 (16:71524269 C>A,G,T), RS1001191405 (16:71529488 G>C), RS1001243750 (16:71529919 G>A,C,T), RS1001345250 (16:71536841 C>T), RS1002022117 (16:71534744 C>T), RS1002076165 (16:71534526 T>G), RS1002148760 (16:71535242 G>A), RS1002569708 (16:71538046 G>A), RS1002748787 (16:71531811 A>C,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2239 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
entinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression, increases methylation	2
trichostatin A	increases expression	1
gallium arsenide	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
erastin	increases expression, increases reaction	1
abrine	decreases expression	1
dorsomorphin	increases expression, affects cotreatment	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Zoledronic Acid	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Cadmium	decreases expression, increases abundance	1
Doxycycline	increases reaction, increases expression	1
Estradiol	affects cotreatment, decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Progesterone	decreases expression	1
Smoke	decreases expression, increases abundance	1
Tobacco Smoke Pollution	affects expression	1
Tretinoin	decreases expression	1
Valproic Acid	affects expression	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	decreases expression, increases abundance	1
Particulate Matter	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL681180	Binding	Inhibitory activity of compound was determined against human high endothelial cell (HEC) GlcNAc-6-ST sulfotransferase at 100 uM	Tyrosylprotein sulfotransferase inhibitors generated by combinatorial target-guided ligand assembly. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.